ReportClinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
Section snippets
Patients
Eligible patients included men and women age 18 years and older with plaque psoriasis of at least 1-year duration and involving 5% or more of their body surface area. Patients had active psoriasis despite topical therapies and were all naive to anti-TNF treatment. Concomitant psoriasis therapies were not allowed with the exception of low- to mid-potency corticosteroids applied topically to the palms, soles, face, and groin. The washout period for prior psoriasis therapies was 2 weeks for
Patients
A total of 148 patients were randomized and 147 patients received at least one dose of study medication and were included in the efficacy analyses; one patient was randomized to the eow group, but did not receive study drug because of withdrawal of informed consent (Fig 2). The first study patient was screened in March 2003, and the last patient's final study visit was in June 2004. The majority of patients (95% [140 of 147]) completed the initial 12-week study with no differences observed in
Discussion
In this multicenter, randomized, placebo-controlled trial, adalimumab demonstrated both short- and long-term, statistically and clinically significant efficacy in the treatment of psoriasis as assessed by a variety of efficacy measures. At week 12 of the study, 53% of patients who had received 40 mg of adalimumab eow and 80% of patients who had received 40 mg/wk of adalimumab achieved at least PASI 75 compared with 4% of patients who had received placebo (P < .001). The patients treated with
References (22)
- et al.
Psoriasis causes as much disability as other major medical diseases
J Am Acad Dermatol
(1999) - et al.
Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis
Clin Dermatol
(2003) - et al.
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
J Am Acad Dermatol
(2004) - et al.
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial
Lancet
(2005) - et al.
The natural history of psoriasis in 5,600 patients
Dermatologica
(1974) - et al.
Epidemiology of psoriasis: clinical issues
J Invest Dermatol
(1994) - et al.
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient membership survey
Arch Dermatol
(2001) - et al.
Etanercept as monotherapy in patients with psoriasis
N Engl J Med
(2003) Molecular differences in anticytokine therapies
Clin Exp Rheumatol
(2003)- et al.
Adalimumab
Clearance is not a realistic expectation of psoriasis treatment
J Am Acad Dermatol
Cited by (469)
Biologics for Psoriasis
2024, Dermatologic ClinicsPathogenesis, multi-omics research, and clinical treatment of psoriasis
2022, Journal of AutoimmunityImmunobiologicals in dermatology
2022, Anais Brasileiros de DermatologiaCitation Excerpt :This drug was initially approved by the FDA for rheumatoid arthritis (RA) and psoriatic arthritis (PA), when improvement in skin lesions was observed, allowing studies with a focus on the indication for plaque psoriasis to be carried out. The drug arrived in Brazil in 2005 and had its biosimilar regulated by ANVISA in 2017.6 It consists of a recombinant fusion protein that binds to the p75 Fc fraction of human immunoglobulin G1 (IgG1), blocking the TNF-α receptor.
Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents
2022, Journal of Allergy and Clinical Immunology
Supported by Abbott Laboratories.
Disclosure: Dr Gordon has received research support and honoraria and is a consultant for Abbott. Dr Langley is an investigator and has received research funding to conduct research studies with Abbott. Dr Leonardi is a consultant and speaker for Abbott. Dr Menter has received honoraria and is a consultant for Abbott. Dr Kang is an ad-hoc consultant for Abbott. Dr Heffernan is a consultant for and has received research funding from Abbott. Drs Zhong, Hoffman, and Okun and Ms Lim are full-time employees of Abbott.
Presented in part at the following annual meetings of the American Academy of Dermatology: February 6-11, 2004, in Washington, DC, and February 18-22, 2005 in New Orleans, Louisiana, as well as at the following annual meetings of the European Academy of Dermatology and Venerology: October 12-16, 2005, in London, UK, and February 9-12, 2006 in Saariselkä, Lapland, Finland.